Exposure to airborne pollutants, which is rising as a result of climate change, appears to increase the risk of Parkinson’s disease, according to a review study into how a changing environment can affect human health. Air pollutants and other aspects of climate change also were found to associate with…
Metabolon is teaming up with Tracking Parkinson’s, the world’s largest long-term study into Parkinson’s disease, to identify novel metabolic biomarkers of disease progression. The discoveries may lead to personalized treatments and better patient care. “We are extremely enthusiastic about partnering with Tracking Parkinson’s to further the understanding…
The small molecule anle138b, an experimental therapy for Parkinson’s disease, was shown in a study to bind to lipidic (fat) fibrils in alpha-synuclein protein clumps, suggesting it could also offer a new diagnostic approach for the disease. “The promising drug candidate anle138b … binds to lipidic alpha-synuclein structures. The drug…
The U.S. Food and Drug Administration (FDA) has given h2o therapeutics 510(k) marketing clearance for its Parky app that monitors motor symptoms in Parkinson’s patients via measurements recorded by an Apple Watch. “As a woman-founded, non [venture capital]-backed company based in Turkey, receiving our first 510(k) clearance is…
The Parkinson’s Foundation has launched a new education series for healthcare professionals to improve the treatment and health outcomes of people with Parkinson’s disease. The Education Series for Community Providers, developed in collaboration with the CVS Health Foundation, seeks to expand patients’ access to high quality healthcare…
Variations in small, repetitive DNA sequences called short tandem repeats (STRs) are associated with an altered risk of developing Parkinson’s disease, a new study reports. “We demonstrate for the first time that these complex repeat regions in fact influence a person’s risk of disease and chip away at understanding…
Highland Instruments will use its new technology — called the Integrated Motion Analysis Suite or IMAS — to objectively improve the evaluation of motor function in Parkinson’s disease patients undergoing treatment with its novel noninvasive brain stimulation device, called Electrosonic Stimulation (ESStim). IMAS will now be included in an…
Early studies in nerve cells and a rat model of Parkinson’s disease support the potential of fosgonimeton, also known as ATH-1017, to be neuroprotective and possibly disease modifying, Athira Pharma, the therapy’s developer, reported. Data from preclinical work showed that the therapy increased cell survival in the…
InMed Pharmaceuticals will launch a new program – the INM-900 series – that will investigate the therapeutic potential of its cannabinoid analogs in neurodegenerative diseases, including Parkinson’s, the company announced in a press release. Cannabinoids, also called phytocannabinoids, are the active chemicals that give the cannabis plant…
DiagnaMed Holdings will develop a virtual reality and artificial intelligence tool (VR/AI Neuro) for the diagnosis of neurodegenerative diseases, such as Parkinson’s disease. The company acquired an exclusive worldwide license of intellectual property from the KU Center for Technology Commercialization, at the University of Kansas, for the…
Get regular updates to your inbox.